Luciana Kase Tanno, MD, PhD, HDR (CHU de Montpellier, Montpellier, France)
Davide Caimmi, PhD, Tenure (CHU de Montpellier, Montpellier, France)
Luc Colas, MD, PhD (CHU de Nantes, Nantes, France)
Isabella Annesi-Maesano, MD, PhD, DSc (Idesp, Inserm, université de Montpellier, CHU de Montpellier, Montpellier, France), Grégory Bouchaud, PhD (université de Nantes, , France), Marco Caminati, MD (Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy), Razvigor Darlenski, MD, PhD, DSc (Tokuda Hospital Sofia, Sofia, Bulgaria), Puya Dehgani-Mobaraki, MD (Healthy Nose Association, San Mariano, Italy), Pascal Demoly, MD, PhD (CHU de Montpellier, Montpellier, France), Ves Dimov, MD (Cleveland Clinic Florida, Weston, Florida, USA), Jean-Luc Fauquert, MD, PhD (CHU de Clermont-Ferrand, Clermont Ferrand, France), Brian Kelly, MD, MA (Midwest Allergy and Asthma Clinic, P.C., Omaha, Nebraska, USA), Agnes Leung, MBChB, MRCPCH, FHKCPaed, FHKAM(Paed) (The Chinese University of Hong Kong, Hong Kong, Hong Kong), Alessandro Marcon, PhD (University of Verona, Verona, Italy), Dean Naisbitt, PhD (University of Liverpool, Liverpool, UK), Duy Le Pham, MD, PhD (University of Medicine and Pharmacy Ho Chi Minh City, Ho Chi Minh City, Viet Nam), Guillaume Pouessel, MD, PhD (centre hospitalier de Roubaix, Roubaix, France), Silvia Sánchez-García, M.D, PhD (Jesus Child University Hospital for Children, Madrid, Spain), Olympia A. Tsilochristou, PhD (Guy's and St Thomas' NHS Foundation Trust, London, UK), Joana Vitte, MD, PhD (université de Reims Champagne-Ardenne, Reims, France)
The Journal of Allergy and Hypersensitivity Diseases (JAHD) is a peer-reviewed, open-access journal in the fields of allergy and immunology. It covers all aspects of the fields, including clinical, educational, and translational research, associated with new technologies, epidemiology, public health and environmental aspects. JAHD is an international platform for promoting and disseminating findings in quality original articles, guidelines, reviews, and short communications to a wide audience.
The JAHD supports modern and traditional approaches and public health strategies to improve the quality care of patients with allergy, asthma and hypersensitivity. An international team of experts counts as part of the editorial board and reviewers, who ensure dynamic peer-review and timely high impact scientific publications.
All JAHD content will be peer-reviewed. The journal welcomes original articles covering the spectrum of conditions managed by allergists in clinical practice, such as:
The JAHD will present results from these areas in original papers, review articles and short communications. This research must advance the understanding of an allergic condition or medical treatment and contribute to improving the quality of care of patients with allergy, asthma, and hypersensitivity.
The JAHD will consider articles, reviews, technical notes and letters to the editors for publication, provided that the methodology and the scientific content are of high quality and the results have substantial clinical impact.
The journal will be published in e-only format and 2 issues in the first year, 4 issues in the second, third and fourth years, and every 2 months in year 5 and after (6 issues per year). The journal will use a fast production workflow, with article-based publishing and article numbering.
Article quality will be assured by an international and gender-balanced editorial board nominated by the editor-in-chief.
The Journal of Allergy and Hypersensitivity Diseases (JAHD) is a peer-reviewed, open-access journal in the fields of allergy and immunology. It covers all aspects of the fields, including clinical, educational, and translational research, associated with new technologies, epidemiology, public health and environmental aspects. JAHD is an international platform for promoting and disseminating findings in quality original articles, guidelines, reviews, and short communications to a wide audience.
The JAHD supports modern and traditional approaches and public health strategies to improve the quality care of patients with allergy, asthma and hypersensitivity. An international team of experts counts as part of the editorial board and reviewers, who ensure dynamic peer-review and timely high impact scientific publications.
All JAHD content will be peer-reviewed. The journal welcomes original articles covering the spectrum of conditions managed by allergists in clinical practice, such as:
The JAHD will present results from these areas in original papers, review articles and short communications. This research must advance the understanding of an allergic condition or medical treatment and contribute to improving the quality of care of patients with allergy, asthma, and hypersensitivity.
The JAHD will consider articles, reviews, technical notes and letters to the editors for publication, provided that the methodology and the scientific content are of high quality and the results have substantial clinical impact.
The journal will be published in e-only format and 2 issues in the first year, 4 issues in the second, third and fourth years, and every 2 months in year 5 and after (6 issues per year). The journal will use a fast production workflow, with article-based publishing and article numbering.
Article quality will be assured by an international and gender-balanced editorial board nominated by the editor-in-chief.
Article publishing charge for open access
*This discount is valid for all authors who wish to publish open access and submit their article by 15 October 2024.
EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.
En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.
Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.